-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
OKYO Pharma (NASDAQ:OKYO) Trading Down 2.9%
OKYO Pharma (NASDAQ:OKYO) Trading Down 2.9%
OKYO Pharma Limited (NASDAQ:OKYO – Get Rating)'s share price was down 2.9% during mid-day trading on Wednesday . The stock traded as low as $2.11 and last traded at $2.15. Approximately 1,731 shares were traded during trading, a decline of 95% from the average daily volume of 34,683 shares. The stock had previously closed at $2.22.
OKYO Pharma Stock Performance
The company's 50-day moving average is $2.14 and its 200-day moving average is $2.28.
About OKYO Pharma
(Get Rating)
OKYO Pharma Limited, a preclinical biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead product includes OK-101 for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic ocular pain.
See Also
- Get a free copy of the StockNews.com research report on OKYO Pharma (OKYO)
- Lucid Motors Faces a Reality That May Cloud a Bullish Perception
- Institutions Put Bottom In Rite Aid Shares
- Here's Why You Should Steer Clear of the FedEx Bounce
- Why Did Viking Therapeutics Stock Skyrocket
- NIKE, Inc Swooshes Higher On Results And Outlook
Receive News & Ratings for OKYO Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OKYO Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
OKYO Pharma Limited (NASDAQ:OKYO – Get Rating)'s share price was down 2.9% during mid-day trading on Wednesday . The stock traded as low as $2.11 and last traded at $2.15. Approximately 1,731 shares were traded during trading, a decline of 95% from the average daily volume of 34,683 shares. The stock had previously closed at $2.22.
纳斯达克股价周三午盘下跌2.9%,最低报2.11美元,尾盘报2.15美元。当日成交量约为1,731股,较日均成交量34,683股下跌95%。此前该股收盘价为2.22美元。
OKYO Pharma Stock Performance
Okyo Pharma股票表现
The company's 50-day moving average is $2.14 and its 200-day moving average is $2.28.
该公司50日移动均线切入位在2.14美元,200日移动均线切入位在2.28美元。
About OKYO Pharma
大代制药公司简介
(Get Rating)
(获取评级)
OKYO Pharma Limited, a preclinical biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead product includes OK-101 for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic ocular pain.
Okyo Pharma Limited是一家临床前生物制药公司,致力于为英国患有炎症性眼病和眼痛的患者开发治疗药物。其主导产品包括用于治疗干眼病的OK-101。该公司还在开发OK-201,一种牛肾上腺髓质,脂化肽临床前类似物,用于治疗神经性眼痛。
See Also
另请参阅
- Get a free copy of the StockNews.com research report on OKYO Pharma (OKYO)
- Lucid Motors Faces a Reality That May Cloud a Bullish Perception
- Institutions Put Bottom In Rite Aid Shares
- Here's Why You Should Steer Clear of the FedEx Bounce
- Why Did Viking Therapeutics Stock Skyrocket
- NIKE, Inc Swooshes Higher On Results And Outlook
- 免费获取StockNews.com关于Okyo Pharma(Okyo)的研究报告
- Lucid Motors面临的现实可能会给看涨的看法蒙上阴影
- 机构将Rite Aid的股票跌至谷底
- 这就是为什么你应该避开联邦快递的反弹
- 维京治疗公司股票为何暴涨
- 耐克公司业绩和前景走高
Receive News & Ratings for OKYO Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OKYO Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
接受《大代医药日报》的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对Okyo Pharma和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧